Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Summary

To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.

Timeline

Start

2010-10

Primary completion

2014-12

Completion

2014-12

Drugs

Indications